Skip to content

Efficacy and persistence of same-day re-start with B/F/TAF among patients with HIV who experienced discontinuation from previous NNRTI based regimens in China

Efficacy and persistence of same-day re-start with B/F/TAF among patients with HIV who experienced discontinuation from previous NNRTI based regimens in China

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098605
Enrollment
Unknown
Registered
2025-03-11
Start date
2025-03-18
Completion date
Unknown
Last updated
2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acquired Immune Deficiency Syndrome

Interventions

AIDS patients who discontinued NNRTI for more than 90 days:Same-day restart of B/F/TAF among HIV patients who experienced discontinuation from previous NNRTI-based regimens

Sponsors

National center for AlDS/STD control and prevention, China CDC
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients with 18 years old or above. 2. Discontinuation of previous NNRTI based regimen for more than 90 days. 3. No known CrCl< 30mL/min or severe hepatic impairment. 4. No known or suspected resistance to BIC. 4. No known pregnancy

Exclusion criteria

Exclusion criteria: 1. Patients who are pregnant. 2. Patients who have abnormal liver and kidney function indicators(Child-pugh class C, CrCl< 30). Hepatitis virus co-infection does not serve as an exclusion criterion. 3. Patients who have historic resistance test indicating drug resistant to BIC or baseline resistance test indicating resistance to BIC. 4. Patients who are psychiatric illness or active tuberculosis co-infection.

Design outcomes

Primary

MeasureTime frame
HIV-RNA test results;

Secondary

MeasureTime frame
The reasons for discontinuation of B/F/TAF;HIV-RNA test results;Demographic characteristics;Parameters of quality of life and treatment satisfaction;Safety and tolerability on B/F/TAF;Drug resistance;The reasons of for discontinuation of prior therapy;

Countries

China

Contacts

Public ContactZhao Yan

National center for AlDS/STD control and prevention, China CDC

zhaoyan@chinaaids.cn+86 10 5890 0927

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026